PATENT CLAIM ANALYSIS

Application Number: 15769844
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-11
Patent Classification: ["514", "227800"]

Abstract:
A compound represented by general formula [I] wherein X represents N or the like, Y represents CH or the like; R A  represents a cycloalkyl group which may be substituted or the like, R 1  represents an alkyl group or the like, R 2  represents an alkyl group which may be substituted or the like, R 3  represents a hydrogen atom or an alkyl group, or a pharmaceutically acceptable salt thereof has an inhibitory activity on aldosterone synthetase, and is useful as a prophylactic and/or therapeutic agent for various diseases or symptoms associated with aldosterone.

Claim (Index 10):
The compound according to  claim 9 , wherein\n substituents of the aryl group which may be substituted, and the 6- to 10-membered monocyclic or bicyclic heteroaryl group which may be partially hydrogenated and may be substituted, represented by R A , are 1-3 groups each independently selected from the group consisting of a halogen atom, a cyano group, an alkyl group, a haloalkyl group, an alkoxyalkyl group, and an alkoxy group, in the aryl group which may be substituted, represented by R A , the aryl moiety is phenyl, or naphthyl, in the 6- to 10-membered monocyclic or bicyclic heteroaryl group which may be partially hydrogenated and may be substituted, represented by R A , the heteroaryl moiety is pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, thiazinyl, triazinyl, indolyl, isoindolyl, indazolyl, benzimidazolyl, benzothiazolyl, benzofuranyl, quinolyl, isoquinolyl, imidazopyridyl, or benzopyranyl; a substituent of (i) the alkyl group which may be substituted, represented by R 2 , is 1-3 groups independently selected from the group consisting of a halogen atom; a hydroxyl group; an oxo group; a carbamoyl group which may be substituted with 1-2 alkyl groups; an alkylsulfonyl group; an alkoxy group which may be substituted with a carbamoyl group which may be substituted with 1-2 alkyl groups; an aliphatic heterocyclic group which may be substituted with 1-3 groups independently selected from the group consisting of a hydroxyl group, an oxo group, an alkyl group, an alkylsulfonyl group, and an alkoxycarbonyl group; an alkoxycarbonyl group; an amino group which may be substituted with 1-2 groups independently selected from the group consisting of an alkyl group and an alkanoyl group; and a heteroaryl group, substituents of (ii) the cycloalkyl group which may be substituted, and (iii) the aliphatic heterocyclic group which may be substituted, represented by R 2 , are 1-3 groups each independently selected from the group consisting of a halogen atom; a hydroxyl group; an oxo group; an alkyl group which may be substituted with 1-3 groups independently selected from the group consisting of a hydroxyl group, a carbamoyl group which may be substituted with 1-2 alkyl groups, and an alkylsulfonyl group; an alkoxy group which may be substituted with a carbamoyl group which may be substituted with 1-2 alkyl groups; an aliphatic heterocyclic group which may be substituted with 1-3 groups independently selected from the group consisting of a hydroxyl group, an oxo group, an alkyl group, an alkylsulfonyl group, and alkoxycarbonyl group; an alkoxycarbonyl group; an amino group which may be substituted with 1-2 groups independently selected from the group consisting of an alkyl group and an alkanoyl group; and a heteroaryl group, in the respective substituents of the above (i) to (iii), the aliphatic heterocyclic group is a group independently selected from the group consisting of piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, and tetrahydropyranyl, in the respective substituents of the above (i) to (iii), the heteroaryl group is independently a pyrimidinyl group, in the aliphatic heterocyclic group which may be substituted, represented by R 2 , the heterocyclic moiety is pyrrolidinyl, piperidinyl, tetrahydrothiopyranyl, tetrahydropyranyl, 1-azabicyclo[2.2.2]octyl(quinuclidinyl), 8-azabicyclo[3.2.1]octyl, 3-oxabicyclo[3.3.1]nonyl, or 3-oxo-9-azabicyclo[3.3.1]nonyl, or a pharmaceutically acceptable salt thereof.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 91.0
- Lexical Diversity: 1.75
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['15305587', '15313407', '15779435', '10583796', '13508905']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8166507530150823
- 35 USC 102 Novelty (BERT): 0.5602335699172399
- Combined Prediction Score: 0.791009034705298
- Mean Citation Score: 322.9079480000001
- Max Citation Score: 436.3854
- Similarity Product: 387.1942114434957

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test